23838-73-5

Basic information

• Product Name: N-Ethylbenzene-1,2-diamine
• Synonyms: N-Ethyl-1,2-benzenediamine;N-Ethylbenzene-1,2-diamine;N-Ethyl-1,2-phenylenediamine 2HCl;(2-aminophenyl)-ethyl-amine;1,2-Benzenediamine, N-ethyl-;N1-ethylbenzene-1,2-diamine;N1-ethylbenzene-1,2-diaminehydrochloride
• CAS NO: 23838-73-5
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.2
• Mol File: 23838-73-5.mol
• Article Data: 31

Chemical Properties

• Melting Point: 185-187 °C (decomp)
• Boiling Point: 263.2°Cat760mmHg
• Flash Point: 130.3°C
• Appearance: /
• Density: 1.066g/cm³
• Vapor Pressure: 0.0105mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.00±0.10(Predicted)
• CAS DataBase Reference: N-Ethylbenzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Ethylbenzene-1,2-diamine(23838-73-5)
• EPA Substance Registry System: N-Ethylbenzene-1,2-diamine(23838-73-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 23838-73-5(Hazardous Substances Data)

Usage

General Description

N-Ethylbenzene-1,2-diamine, also known as N,N'-diethyl-1,2-phenylenediamine, is a chemical compound commonly used in the production of hair dyes and other hair coloring products. It is a derivative of benzene and is composed of two ethyl groups attached to the carbon atoms in the 1 and 2 positions of the benzene ring. N-Ethylbenzene-1,2-diamine functions as a color developer in hair dyes, helping to produce the desired color by reacting with the dye molecules. However, this chemical has been reported to have potential skin and respiratory irritant properties, as well as being a possible allergen, and as such, it should be handled with caution and proper protective measures.

InChI:InChI=1/C8H12N2/c1-2-10-8-6-4-3-5-7(8)9/h3-6,10H,2,9H2,1H3

Upstream product

• 1222062-44-3 2-[(2-ethylaminophenylamino)methylene]malonic acid diethyl ester 
• 88-74-4 2-nitro-aniline 
• 74-96-4 ethyl bromide 
• 95-54-5 1,2-diamino-benzene 
• 121-44-8 triethylamine 
• 88-73-3 2-Chloronitrobenzene 
• 115749-32-1 phenyl-3 N-ethyl N-(amino-2 phenyl)amino-5 isoxazole 
• 1493-27-2 ortho-nitrofluorobenzene 
• 105-58-8 Diethyl carbonate 
• 78662-07-4 1,3-dihydro-1-ethyl-4-phenyl-1,5-benzodiazepin-2-one 
• 122-52-1 triethyl phosphite 
• 10112-15-9 N-Ethyl-2-nitroaniline 

Downstream Products

• 10045-45-1 N-ethylbenzimidazolinone 
• 89767-19-1 C₃₂H₃₆N₈P₄ 
• 124-40-3 dimethyl amine 
• 3785-64-6 (1-ethyl-1H-benzoimidazol-2-yl)-phenyl-methanol 
• 65463-70-9 2-(4-chloro-3-methyl-phenoxy)-1-ethyl-2,3-dihydro-1H-benzo[1,3,2]diazaphosphole 2-oxide 
• 5805-76-5 1-ethyl-2-methyl-1H-benzo[d]imidazole 
• 7035-68-9 1-Ethylbenzimidazole 
• 6528-75-2 1-ethyl-2-phenyl-1H-benzo[d]imidazole 
• 1186528-13-1 1-ethyl-3-{[(4-methylphenyl)sulfonyl]methyl}quinoxalin-2(1H)-one 
• 1186528-12-0 1-ethyl-3-{[(4-methylphenyl)thio]methyl}quinoxalin-2(1H)-one 
• 1186527-86-5 3-(4-chlorophenyl)-1-ethylquinoxalin-2(1H)-one 
• 66947-93-1 2-(chloromethyl)-1-ethyl-1H-benzo[d]imidazole 
• 1025506-24-4 (R)-4-chloro-N-(1-(1-ethyl-1H-benzo[d]imidazol-2-yl)ethyl)-benzenesulfonamide 

Relevant articles and documents

Synthesis and antiproliferative activity of benzimidazole-based, trinuclear neutral cyclometallated and cationic, N^N-chelated ruthenium(ii) complexes

A series of 2-phenyl and 2-pyridyl tris-benzimidazole ligands was reacted with the [Ru(p-cymene)Cl2]2 dimer to yield the corresponding neutral cyclometallated and cationic organoruthenium(ii) complexes. All of the synthesized compoun

Design, synthesis and biological evaluation of 5-fluorouracil-derived benzimidazoles as novel type of potential antimicrobial agents

A series of 5-fluorouracil benzimidazoles as novel type of potential antimicrobial agents were designed and synthesized for the first time. Bioactive assay manifested that some of the prepared compounds exhibited good or even stronger antibacterial and an

In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors

The lack of effective therapies for epileptic patients and the potentially harmful consequences of untreated seizure incidents have made epileptic disorders in humans a major health concern. Therefore, new and more potent anticonvulsant drugs are continually sought after,?to combat epilepsy. On the basis of the pharmacophoric structural specifications of effective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists with an efficient anticonvulsant activity, the present work reports the design and synthesis of two novel sets of quinoxaline derivatives. The anticonvulsant activity of the synthesized compounds was evaluated in vivo according to the pentylenetetrazol-induced seizure protocol, and the results were compared with those of perampanel as a reference drug. Among the synthesized compounds, 24, 28, 32, and 33 showed promising activities with ED50 values of 37.50, 23.02, 29.16, and 23.86 mg/kg, respectively. Docking studies of these compounds suggested that AMPA binding could be the mechanism of action of these derivatives. Overall, the pharmacophore-based structural optimization, in vivo?and in silico docking, and druglikeness studies indicated that the designed compounds could serve as promising candidates for the development of effective anticonvulsant agents with good pharmacokinetic profiles.